share_log

Unveiling 11 Analyst Insights On Bristol-Myers Squibb

Unveiling 11 Analyst Insights On Bristol-Myers Squibb

揭示了有關施貴寶的11個分析師見解
Benzinga ·  10/08 02:00
11 analysts have shared their evaluations of Bristol-Myers Squibb (NYSE:BMY) during the recent three months, expressing a mix of bullish and bearish perspectives.
在最近三個月內,有11位分析師針對施貴寶(紐交所:BMY)進行了評估,表達了看好和看淡觀點的混合態度。
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
在下表中,您將找到他們最近的評級摘要,揭示了過去30天內情緒的變化,並將它們與前幾個月進行比較。
Insights from analysts' 12-month price targets are revealed, presenting an average target of $48.0, a high estimate of $59.00, and a low estimate of $41.00. This current average reflects an increase of 2.32% from the previous average price target of $46.91.
分析師對12個月的目標價格的見解顯示,平均目標爲48.0美元,最高估值爲59.00美元,最低估值爲41.00美元。當前平均數反映了與之前46.91美元的平均目標價格相比的2.32%的增長。
Decoding Analyst Ratings: A Detailed Look
分析師評級解讀:詳細解析
The analysis of recent analyst actions...
最近分析師行...

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論